DOVAUnknown

Dova Pharmaceuticals Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Dova Pharmaceuticals Inc. (DOVA), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are DOVA insiders buying or selling?

Dova Pharmaceuticals Inc. insiders reported 23 open-market buys ($25.5M) and 15 sells ($872.0K) across 38 Form 4 filings — a net buying position of $24.6M.

Source: SEC EDGAR Form 4

Key Statistics (as of Oct 2, 2019)

Total Form 4 filings
38
SEC EDGAR
Insider filers
11
Insider buys (23)
$25.5M
Insider sells (15)
$872.0K

Insider sentiment

Net buying

Net insider flow of $24.6M in net buying.

Recent DOVA insider transactions

DateInsiderRoleTypeSharesPriceValue
Oct 2, 2019David ZaccardelliPresident & CEOSale5.3K$27.90$147.2K
Oct 2, 2019Phd F Allen Lee MDChief Medical OfficerSale978$28.00$27.4K
Oct 2, 2019Mark W HahnChief Financial OfficerSale775$28.00$21.7K
Oct 2, 2019Jason HoittChief Commercial OfficerSale2.4K$28.00$66.8K
Oct 2, 2019Kevin LaliberteSr. VP, Product DevelopmentSale3.7K$28.00$103.5K
Sep 27, 2019Kevin LaliberteSr. VP, Product DevelopmentSale3.1K$20.00$62.0K
Aug 12, 2019Manning Paul BDirector, 10% OwnerPurchase28.1K$15.87$445.3K
Aug 1, 2019Kevin LaliberteSr. VP, Product DevelopmentSale1.4K$15.97$22.2K
Jul 16, 2019Jason HoittChief Commercial OfficerSale7.6K$15.26$115.7K
Jul 12, 2019Joseph Edelman10% OwnerPurchase85.1K$16.68$1.4M
Jul 9, 2019Joseph Edelman10% OwnerPurchase50.0K$16.46$823.0K
Jul 4, 2019Joseph Edelman10% OwnerPurchase20.5K$14.51$298.0K
Jul 3, 2019David ZaccardelliPresident & CEOSale10.4K$15.94$166.6K
Jul 2, 2019Mark W HahnChief Financial OfficerSale1.5K$14.17$21.9K
Jul 2, 2019Roger JeffsDirectorSale1.3K$14.17$18.5K
Jul 2, 2019Kevin LaliberteSr. VP, Product DevelopmentSale1.2K$14.17$16.9K
Jul 2, 2019Phd F Allen Lee MDChief Medical OfficerSale2.0K$14.19$27.8K
Jul 2, 2019Jason HoittChief Commercial OfficerSale2.4K$13.81$33.0K
Jul 1, 2019Joseph Edelman10% OwnerPurchase427.2K$13.35$5.7M
Apr 10, 2019Jason HoittChief Commercial OfficerSale2.4K$8.77$20.9K
Mar 8, 2019Manning Paul BDirector, 10% OwnerPurchase68.0K$7.48$508.6K
Dec 21, 2018Roger JeffsDirectorPurchase30.0K$6.22$186.6K
Dec 21, 2018David ZaccardelliPresident & CEOPurchase10.0K$6.07$60.7K
Dec 21, 2018Manning Paul BDirector, 10% OwnerPurchase128.5K$6.48$832.1K
Dec 21, 2018John A Stalfort IIIDirectorPurchase31.0K$6.26$194.1K

Showing the 25 most recent of 38 Form 4 filings for Dova Pharmaceuticals Inc..

Most active DOVA insiders

  • Joseph Edelman10 filings
  • Manning Paul B6 filings
  • Jason Hoitt4 filings
  • Kevin Laliberte4 filings
  • David Zaccardelli3 filings

Ask anything about DOVA insider activity

Use Trabud's AI agent to query Dova Pharmaceuticals Inc.'s Form 4 history in plain English — "Show me DOVA CEO purchases this year" or compare it against any other ticker.

Open the AI agent

DOVA insider trading FAQ

Are Dova Pharmaceuticals Inc. insiders buying or selling?

Across 38 SEC Form 4 filings, Dova Pharmaceuticals Inc. (DOVA) insiders reported 23 open-market purchases totaling $25.5M and 15 sales totaling $872.0K. That is a net buying position of $24.6M.

How many insiders trade DOVA stock?

11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Dova Pharmaceuticals Inc.. The most recent filing was accepted on Oct 2, 2019.

Where does Trabud get DOVA insider trading data?

All DOVA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content